Lv3
230 积分 2023-04-21 加入
Multiple endocrine neoplasia type 1 (MEN1): recommendations and guidelines for best practice
2小时前
待确认
OA02.02 Molecular Residual Disease (MRD) Analysis from NeoADAURA: Neoadjuvant Osimertinib ± Chemotherapy in Resectable EGFRm NSCLC
5小时前
求助中
BFAST but be smart: bTMB remains an exploratory biomarker in NSCLC
5天前
已完结
Nationwide Study on Factor V Deficiency in China: Clinical Characteristics, Genotype, and Treatment Approaches
7天前
已完结
Tumour mutational burden: clinical utility, challenges and emerging improvements
9天前
已完结
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
9天前
已完结
Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab
12天前
已完结
A Genomic Alteration in GATA3 Affects Treatment Responses With a CDK4/6 Inhibitor Collaborating With p18INK4C Expression in Advanced Breast Carcinoma
27天前
已关闭
DPYD Genotyping Recommendations
29天前
已完结
UGT1A1 Testing in Breast Cancer: should it become routine practice in patients treated with antibody-drug conjugates?
1个月前
已完结
皖公网安备34019202002308
